Shenzhen Chipscreen Biosciences Co., Ltd. (SHA:688321)
25.25
+0.65 (2.64%)
Jun 12, 2026, 3:00 PM CST
SHA:688321 Revenue
Shenzhen Chipscreen Biosciences had revenue of 257.04M CNY in the quarter ending March 31, 2026, with 58.41% growth. This brings the company's revenue in the last twelve months to 1.00B, up 45.71% year-over-year. In the year 2025, Shenzhen Chipscreen Biosciences had annual revenue of 910.06M with 38.32% growth.
Revenue (ttm)
1.00B
Revenue Growth
+45.71%
P/S Ratio
11.13
Revenue / Employee
1.00M
Employees
1,002
Market Cap
11.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 910.06M | 252.11M | 38.32% |
| Dec 31, 2024 | 657.95M | 134.24M | 25.63% |
| Dec 31, 2023 | 523.71M | -6.23M | -1.18% |
| Dec 31, 2022 | 529.94M | 99.49M | 23.11% |
| Dec 31, 2021 | 430.45M | 160.98M | 59.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Hisun Pharmaceutical | 10.31B |
| Shanghai Shyndec Pharmaceutical | 8.82B |
| Zhejiang Medicine | 8.82B |
| Zhejiang CONBA Pharmaceutical | 6.69B |
| Zhejiang Jiuzhou Pharmaceutical | 5.22B |
| Zhejiang Jingxin Pharmaceutical | 4.04B |
| Mayinglong Pharmaceutical Group | 3.91B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.99B |